National Test Systems, LLC

National Test Systems, LLC, based in the US, delivers innovative rapid point-of-care diagnostic testing solutions, focusing on drug detection, infectious diseases, and fertility assessments across various settings. National Test Systems, LLC specializes in rapid point-of-care diagnostic testing solutions. Founded in 2001 and headquartered in Boca Raton, US, the company has executed one deal as of November 2025. The founder's prior experience is not mentioned, nor are there any known pivots in business strategy or subsidiaries.

National Test Systems (NTS) specializes in rapid point-of-care diagnostic testing solutions, offering a diverse array of products designed for the detection of drugs of abuse, infectious diseases, and fertility-related conditions. Their core offerings include urine cup tests, urine dip tests, oral swab tests, and CLIA-waived tests, engineered to provide fast, accurate, and reliable results in various settings, such as workplaces, corporate environments, and government programs. These solutions address critical end-use cases, including workplace safety through drug screening, timely diagnosis of infections like COVID-19, influenza, and strep throat, as well as fertility assessments through pregnancy testing. NTS caters to a broad client base that includes healthcare providers, laboratories, and corporations across the United States, with expansion efforts into additional geographical markets as the demand for point-of-care testing solutions grows.

NTS generates revenue primarily through the sale of diagnostic testing products and associated services, structured around B2B transactions with healthcare providers and organizations running testing programs. Clients typically purchase testing kits and solutions either through direct sales or partnerships, which may include subscription models for ongoing supply and support. The firm’s flagship products, such as their rapid testing solutions for drugs of abuse and infectious diseases, are priced competitively to meet the needs of various client segments, from small clinics to large healthcare networks. Revenue is further supported by value-added services, such as training and logistical support, ensuring that clients effectively implement and manage their testing programs.

This multifaceted approach enables NTS to maintain strong relationships with its customer base while ensuring the reliability and quality of its testing solutions. In November 2025, Premier Biotech, Inc. , a portfolio company of Align Capital Partners, acquired National Test Systems, LLC. The acquisition enables Premier Biotech, Inc.

to enhance customer base and innovate its drug screening services and capabilities to wider market clients. This strategic move will likely facilitate the development and launch of new diagnostic products while further expanding into new geographic markets. Specific expansion targets and product timelines have not been disclosed.